Prognosis biomarkers for triple-negative breast cancer

A method of predicting a risk of cancer recurrence in a triple-negative breast cancer (TNBC) patient by a signature of miRNA gene products, the method comprising:

• providing a breast cancer sample from the TNBC patient, the breast cancer sample negatively expressing biomarkers comprising estrogen (ER), progesterone (PR), and human epithelial receptor 2 (HER2) determined by immunohistochemical staining;
• measuring an expression level of each of a combination of miRNAs in the breast cancer sample, wherein the combination of miRNAs consists of hsa-miR-139-5p, hsa-miR-10b-5p, hsa-miR-486-5p, hsa-miR-455-3p, hsa-miR-107, hsa-miR-146b-5p, hsa-miR-324-5p, and hsa-miR-20a-5p;
• calculating a risk score based on the expression level of the miRNAs, wherein
• the risk score=(0.02554×an expression value of miR-139)+(−0.000005284×an expression value of miR-10b)+(−0.0003305×an expression value of miR-486)+(0.008664×an expression value of miR-107)+(0.003201×an expression value of miR-324)+(0.001031×an expression value of miR-455)+(0.000474×an expression value of miR-146b)+(−0.001575×an expression value of miR-20a);
• and
• comparing the risk score with a reference threshold of 1.602 to determine the risk of cancer recurrence of the TNBC patient, wherein the TNBC patient is predicted to have a high risk when the risk score is equal to or larger than 1.602.